More about

Metastatic Prostate Cancer

News
February 17, 2022
4 min read
Save

Niraparib regimen ‘new first-line option’ for certain men with metastatic prostate cancer

Niraparib regimen ‘new first-line option’ for certain men with metastatic prostate cancer

SAN FRANCISCO  — The addition of niraparib to abiraterone acetate and prednisone improved outcomes for certain men with prostate cancer, according to randomized phase 3 study results presented at ASCO Genitourinary Cancers Symposium.

News
February 17, 2022
3 min read
Save

Polygenic hazard score predicts risk for metastatic, fatal prostate cancer across groups

Polygenic hazard score predicts risk for metastatic, fatal prostate cancer across groups

SAN FRANCISCO  — A novel risk-prediction tool based on 290 genetic variants correctly identified men with high or low lifetime risks for developing metastatic or fatal prostate cancer, according to a study presented at ASCO Genitourinary Cancers Symposium.

News
October 29, 2021
3 min read
Save

Noncancer causes of death ‘increasingly pertinent’ among men with advanced prostate cancer

Noncancer causes of death ‘increasingly pertinent’ among men with advanced prostate cancer

A substantial number of deaths among men with metastatic prostate cancer resulted from noncancer causes, including cardiovascular disease, according to a retrospective cohort study published in JAMA Network Open.

News
September 30, 2021
3 min watch
Save

VIDEO: B7-H3 "promising new agent" for early line and metastatic prostate cancer

VIDEO: B7-H3 "promising new agent" for early line and metastatic prostate cancer

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses two posters on prostate cancer therapies presented at the ESMO Congress 2021.

News
September 30, 2021
1 min watch
Save

VIDEO: Phase 3 trial shows improvement in survival for subset of men with prostate cancer

VIDEO: Phase 3 trial shows improvement in survival for subset of men with prostate cancer

In this video, Alicia Morgans, MD, discusses the PEACE-1 phase 3 trial that found adding abiraterone to androgen deprivation therapy plus docetaxel improves radiographic PFS and OS in men with metastatic castration-sensitive prostate cancer.

News
September 30, 2021
1 min watch
Save

VIDEO: Efficacy shown, toxicity a factor for DS-7300

VIDEO: Efficacy shown, toxicity a factor for DS-7300

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.

News
September 24, 2021
2 min read
Save

Nivolumab plus rucaparib shows ‘noteworthy activity’ in subset of men with prostate cancer

Nivolumab plus rucaparib shows ‘noteworthy activity’ in subset of men with prostate cancer

Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial presented during the virtual ESMO Congress 2021.

News
September 24, 2021
1 min read
Save

Olaparib regimen extends radiographic PFS in metastatic prostate cancer

A randomized phase 3 study that assessed the addition of olaparib to abiraterone as first-line treatment for men with metastatic castration-resistant prostate cancer met its primary endpoint, according to the agent’s manufacturer.

News
September 20, 2021
3 min read
Save

Adding abiraterone acetate to standard of care prolongs survival in prostate cancer subset

Adding abiraterone acetate to standard of care prolongs survival in prostate cancer subset

Adding abiraterone acetate to androgen deprivation therapy plus docetaxel improved radiographic PFS and OS among men with metastatic castration-sensitive prostate cancer, according to data presented during the virtual ESMO Congress 2021.

News
June 17, 2021
1 min read
Save

FDA grants breakthrough designation to radioligand therapy for advanced prostate cancer

FDA grants breakthrough designation to radioligand therapy for advanced prostate cancer

The FDA granted breakthrough therapy designation to 177Lu-PSMA-617 for treatment of metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.

View more